For the first quarter of its fiscal year 2024, HAEMONETICS CORPORATION ($NYSE:HAE) reported total revenue of USD 311.3 million, a 19.1% increase from the same period in the previous fiscal year. Net income grew 106.4% year over year, totalling USD 41.0 million.
The corporation’s stock opened at $94.6 and closed at $89.9, representing an increase of 1.5% from its prior closing price of 88.6. The release of these earnings serves as an indication of the company’s sound financial standing and positive outlook for continued growth in the coming quarters. The success of HAEMONETICS CORPORATION in generating profits this quarter demonstrates the corporation’s ability to capitalize on their resources and make sound investments in order to maximize shareholder value.
This ability to generate consistent profits is what sets HAEMONETICS CORPORATION apart from its competitors within the industry, and it is likely to contribute to further growth and profitability in the future. The corporation’s continued focus on developing innovative products and services is likely to keep the company profitable in the coming year and beyond. Live Quote…
About the Company
Ownership (Institutional/ Fund Holdings)
Below shows the total revenue, net income and net margin for Haemonetics Corporation. More…
Income Statement Reports (Yearly/ Quarterly/ LTM)
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Haemonetics Corporation. More…
Cash Flow Statement (Yearly/ Quarterly/ LTM)
Cash Flow Supplement
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Haemonetics Corporation. More…
Balance Sheet (Yearly/ Quarterly)
Balance Sheet Supplement
||Book Value Per Share
Key Ratios Snapshot
Some of the financial key ratios for Haemonetics Corporation are shown below. More…
Income Statement Ratios
Balance Sheet Ratios
Cash Flow Ratios
Other Supplementary Items
|3Y Rev Growth
||3Y Operating Profit Growth
Analysis – Haemonetics Corporation Stock Fair Value
GoodWhale has conducted an analysis of the fundamentals of HAEMONETICS CORPORATION and has determined that the fair value of its stock is around $95.0. This fair value was calculated using our proprietary Valuation Line. At the current market price of $89.9, the stock is undervalued by 5.3%, suggesting that now may be an opportune time to invest in the company. We believe investors looking for a potentially undervalued stock should consider HAEMONETICS CORPORATION at this time. More…
Risk Rating Analysis
Star Chart Analysis
The company has a wide range of products, including plasma collection systems, platelet and plasma pheresis systems, and whole blood collection systems. Haemonetics Corp. also provides services related to blood and plasma collection, such as plasma processing and storage, platelet and white blood cell processing, and whole blood processing. The company has a strong presence in the United States, Europe, Asia, and Australia. Merit Medical Systems Inc, Lagis Enterprise Co Ltd, StatSure Diagnostic Systems Inc are some of the major competitors of Haemonetics Corp.
– Merit Medical Systems Inc ($NASDAQ:MMSI)
Medtronic is a medical device company that develops and manufactures a wide range of products, from pacemakers to artificial hearts. The company has a market cap of $3.9 billion and a return on equity of 4.51%. Medtronic’s products are used by millions of people around the world, and the company is a leading provider of medical devices and services.
– Lagis Enterprise Co Ltd ($TPEX:6730)
Lagis Enterprise Co Ltd is a publicly traded company with a market capitalization of 1.02 billion as of 2022. The company has a return on equity of 12.12%. Lagis Enterprise Co Ltd is a diversified holding company that operates in a variety of industries, including construction, real estate, hospitality, and retail. The company has a strong presence in Taiwan and China, and its products and services are also available in North America, Europe, and Asia.
– StatSure Diagnostic Systems Inc ($OTCPK:SSUR)
StatSure Diagnostic Systems Inc is a company that manufactures and sells diagnostic products and services. The company has a market cap of 107.06k as of 2022 and a Return on Equity of 15.2%. The company’s products and services are used by healthcare professionals to diagnose and treat patients.
Investors who are looking for growth opportunities should consider HAEMONETICS CORPORATION. The company reported strong results in its first quarter of fiscal year 2024, with total revenue increasing 19.1% year over year and net income growing 106.4% over the same period. This suggests that the company is performing well and may continue to experience growth in the future. Investors should carefully analyze the company’s financials to get a better understanding of its future prospects.